Literature DB >> 11026187

An open trial of plasma exchange in childhood-onset obsessive-compulsive disorder without poststreptococcal exacerbations.

R Nicolson1, S E Swedo, M Lenane, J Bedwell, M Wudarsky, P Gochman, S D Hamburger, J L Rapoport.   

Abstract

Patients with childhood-onset obsessive-compulsive disorder (OCD) with symptom exacerbations following streptococcal infections benefit from treatment with plasma exchange. In this study, 5 patients with treatment-refractory OCD without a history of streptococcus-related exacerbations underwent an open 2-week course of therapeutic plasma exchange. Behavioral ratings, completed at baseline and 4 weeks after the initial treatment, included the Clinical Global Impressions Scale and the Yale-Brown Obsessive Compulsive Scale. All 5 patients completed the trial with few side effects, but none showed significant improvement. Plasma exchange does not benefit children and adolescents with OCD who do not have streptococcus-related exacerbations.

Entities:  

Mesh:

Year:  2000        PMID: 11026187     DOI: 10.1097/00004583-200010000-00020

Source DB:  PubMed          Journal:  J Am Acad Child Adolesc Psychiatry        ISSN: 0890-8567            Impact factor:   8.829


  14 in total

1.  Certain eating disorders may be a neuropsychiatric manifestation of PANDAS: case report.

Authors:  Cynthia V Calkin; Carlo G Carandang
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2007

2.  Five youth with pediatric acute-onset neuropsychiatric syndrome of differing etiologies.

Authors:  Jennifer Frankovich; Margo Thienemann; Sonal Rana; Kiki Chang
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-02       Impact factor: 2.576

3.  Clinical presentation of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections in research and community settings.

Authors:  Susan E Swedo; Jakob Seidlitz; Miro Kovacevic; M Elizabeth Latimer; Rebecca Hommer; Lorraine Lougee; Paul Grant
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-02       Impact factor: 2.576

Review 4.  The immunobiology of Tourette's disorder, pediatric autoimmune neuropsychiatric disorders associated with Streptococcus, and related disorders: a way forward.

Authors:  Tanya K Murphy; Roger Kurlan; James Leckman
Journal:  J Child Adolesc Psychopharmacol       Date:  2010-08       Impact factor: 2.576

Review 5.  Is obsessive-compulsive disorder an autoimmune disease?

Authors:  P D Arnold; M A Richter
Journal:  CMAJ       Date:  2001-11-13       Impact factor: 8.262

6.  Use of intravenous immunoglobulin in the treatment of twelve youths with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections.

Authors:  Miro Kovacevic; Paul Grant; Susan E Swedo
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-02-06       Impact factor: 2.576

7.  Therapeutic plasma apheresis as a treatment for 35 severely ill children and adolescents with pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections.

Authors:  M Elizabeth Latimer; Nathan L'Etoile; Jakob Seidlitz; Susan E Swedo
Journal:  J Child Adolesc Psychopharmacol       Date:  2015-02-06       Impact factor: 2.576

Review 8.  Childhood anxiety disorders and developmental issues in anxiety.

Authors:  Paul Arnold; S Preeya Banerjee; Rashmi Bhandari; Elisa Lorch; Jennifer Ivey; Michelle Rose; David R Rosenberg
Journal:  Curr Psychiatry Rep       Date:  2003-08       Impact factor: 5.285

Review 9.  The usefulness of immunotherapy in pediatric neurodegenerative disorders: A systematic review of literature data.

Authors:  Giovanna Vitaliti; Omidreza Tabatabaie; Nassim Matin; Caterina Ledda; Piero Pavone; Riccardo Lubrano; Agostino Serra; Paola Di Mauro; Salvatore Cocuzza; Raffaele Falsaperla
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

10.  Gluten Ataxia and Post-Streptococcal Central Nervous System Syndromes: Emerging Immune-mediated Disorders of the Central Nervous System?

Authors:  Adrian Wills; Russell Dale; Gavin Giovannoni
Journal:  Curr Treat Options Neurol       Date:  2005-05       Impact factor: 3.972

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.